Jubilant Ingrevia Limited (JUBLINGREA) — Financial Results

1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

📢 Key Event
Jubilant Ingrevia Limited reported Q4 FY26 results with 12% YoY revenue growth to ₹1,179 crores and 11% YoY net profit growth to ₹278 crores.

🔄 What Changed
EBITDA margin expanded to 14% from 11% in FY25; net debt increased to ₹587 crores; capex of ₹69 crores deployed for CDMO expansion.

🔮 What's Next
Sequential revenue growth expected starting Q1FY27; Remidex acquisition to accelerate human nutrition premixes business.

💡 Investor Takeaway
The company is successfully shifting toward higher-margin Specialty Chemicals and Nutrition segments, supported by strategic acquisitions and capacity expansions.

Jubilant Ingrevia Limited reported Q4 FY26 revenue of ₹1,179 crores, up 12% YoY, with EBITDA at ₹607 crores (+9% YoY) and net profit of ₹278 crores (+11% YoY). EBITDA margin improved to 14% from 11% in FY25, driven by pricing pass-throughs and cost initiatives. Specialty Chemicals contributed 44% of revenue and 76% of EBITDA, while Nutrition Health accounted for 18% of revenue and 15% of EBITDA. The company completed its agro CDMO plant in 14 months with first shipments in March 2026 and acquired Remidex Pharma to accelerate human nutrition premixes. Capex of ₹69 crores was deployed for CDMO expansion, with sequential revenue growth expected from Q1FY27. Net debt stood at ₹587 crores, and cash and equivalents were ₹190 crores.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

Revenue: ₹1,179 CrNet Profit: ₹86

📢 Key Event
Jubilant Ingrevia reports Q4 FY26 revenue of ₹1,179 crores, up 12% YoY, with EBITDA at ₹172 crores and net profit of ₹86 crores.

🔄 What Changed
EBITDA margin improved to 15% from prior period; net debt decreased by 11% YoY to ₹587 crores; final dividend recommended at ₹2.5 per share.

🔮 What's Next
FY27 growth outlook mentioned; capacity expansion planned at Gajraula and Bharuch; CDMO capabilities to be expanded.

💡 Investor Takeaway
Shareholders benefit from strong profit growth, improved margins, and a higher dividend payout reflecting robust cash generation.

Jubilant Ingrevia Limited reported Q4 FY26 revenue of ₹1,179 crores, up 12% YoY, with EBITDA at ₹172 crores (11% YoY growth) and net profit of ₹86 crores (17% YoY growth). EBITDA margin improved to 15%, driven by strong performance in Specialty Chemicals (27% margin) and Nutrition & Health (14% margin). The company declared a final dividend of ₹2.5 per share, totaling ₹5 per share for FY26. Strategic progress includes capacity expansions in Gajraula and Bharuch, acquisition of Remidex Pharma, and a shift toward higher-margin Specialty Chemicals (76% of EBITDA). Risks include margin pressure from Middle East disruptions and China oversupply in agrochemicals.

📊 Stock Analysis — JUBLINGREA ✨ Ask AI About This